Breast cancer with overexpression of human epidermal growth factor receptor 2 (HER2) accounted for 20–30% of all breast cancers and had poorer prognosis (Vu and Claret, 2012; Robidoux et al., 2013). Here, ERBB2 is linked to breast cancer.